Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA β-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature. © 2009 The Authors Journal compilation © 2009 European Society of Clinical Microbiology and Infectious Diseases.

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens

CORNAGLIA, Giuseppe;
2009-01-01

Abstract

Multidrug resistance in Gram-positive pathogens emerged as a major therapeutic challenge over two decades ago. The worldwide spread of methicillin-resistant Staphylococcus aureus (MRSA), glycopeptide-resistant enterococci and other resistant Gram-positive pathogens had a major impact on antibiotic policies, and prompted the discovery and development of new antibiotics to combat difficult-to-treat infections caused by such pathogens. Several new antibiotics active against multidrug-resistant Gram-positive pathogens have recently been introduced into clinical practice, and the antibiotic pipeline contains additional anti-Gram-positive drugs at an advanced stage of development, including new glycopeptides (dalbavancin, oritavancin, and telavancin), new anti-MRSA β-lactams (ceftobiprole), and new diaminopyrimidines (iclaprim). This article provides a brief overview of these upcoming agents, partially based on the material presented at the ESCMID Conference entitled 'Fighting infections due to multidrug-resistant Gram-positives' (Venice, Italy, 29-31 May 2008) and on the most recent literature. © 2009 The Authors Journal compilation © 2009 European Society of Clinical Microbiology and Infectious Diseases.
2009
Antimicrobial agents; Gram-positive pathogens; Multidrug resistance; Review; 2 4 diaminopyrimidine derivative; ampicillin; beta lactam antibiotic; carbapenem derivative; cefalexin; ceftaroline; ceftazidime; ceftobiprole; cephalosporin derivative; dalbavancin; dalfopristin plus quinupristin; daptomycin; iclaprim; linezolid; macrolide; oritavancin; penicillin G; placebo; polypeptide antibiotic agent; teicoplanin; telavancin; tigecycline; vancomycin; antibiotic resistance; antibiotic sensitivity; area under the curve; bacterial transmission; bloodstream infection; clinical practice; clinical trial; drug bioavailability; drug dose titration; drug excretion; drug half life; drug mechanism; drug metabolism; drug structure; drug withdrawal; Enterococcus; Gram positive bacterium; Gram positive infection; health care policy human; infection control; infection prevention; maximum plasma concentration; methicillin resistant Staphylococcus aureus; minimum inhibitory concentration; penicillin resistance; pneumonia; priority journal; public health; repeated drug dose; single drug dose; skin infection; Staphylococcus infection; structure activity relation; surgical infection; unspecified side effect; ventilator associated pneumonia; Anti-Bacterial Agents; beta-Lactams; Clinical Trials as Topic; Drug Discovery; Drug Resistance Multiple Bacterial; Glycopeptides; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Pyrimidines; Posibacteria
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/338918
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 51
social impact